TITLE

Factors Associated with Late Antiretroviral Therapy Initiation among Adults in Mozambique

AUTHOR(S)
Lahuerta, Maria; Lima, Josue; Nuwagaba-Biribonwoha, Harriet; Okamura, Mie; Alvim, Maria Fernanda; Fernandes, Rufino; Assan, Americo; Hoos, David; Elul, Batya; El-Sadr, Wafaa M.; Nash, Denis
PUB. DATE
May 2012
SOURCE
PLoS ONE;May2012, Vol. 7 Issue 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes, and onward transmission. Methods: To evaluate individual and clinic-level factors associated with late ART initiation in Mozambique, we conducted a retrospective sex-specific analysis of data from 36,411 adult patients who started ART between January 2005 and June 2009 at 25 HIV clinics in Mozambique. Late ART initiation was defined as CD4 count,100 cells/μL or WHO stage IV. Mixed effects models were used to identify patient- and clinic-level factors associated with late ART initiation. Results: The proportion of patients initiating ART late decreased from 46% to 37% during 2005-2007, but remained constant (between 37-33%) from 2007-2009. Of those who initiated ART late (median CD4 = 57 cells/mL), 5% were known to have died and 54% were lost to clinic within 6 months of ART initiation (compared with 2% and 47% among other patients starting ART [median CD4 = 192 cells/mL]). In multivariate analysis, female sex and pregnancy at ART initiation (AORfemale•not•pregnant•vs.•male = 0.66, 95%CI [0.62-0.69]; AORpregnant•vs.•non•pregnant = 0.60, 95%CI [0.49-0.73]), younger and older age (AOR15-25•vs.26-30 = 0.86, 95%CI [0.79-0.94], AOR.45•vs.26-30 = 0.72, 95%CI [0.67-0.77]), entry into care via PMTCT (AORentry•through•PMTCT•vs.VCT = 0.42, 95%CI [0.35-0.50]), marital status (AORmarried/in union•vs.single = 0.87, 95%CI [0.83-0.92]), education (AORsecondary•or•higher•vs.primary = 0.87, 95%CI [0.83-0.93]) and year of ART initiation were associated with a lower likelihood of late ART initiation. Clinic-level factors independently associated with a lower likelihood of late ART initiation included CD4 machine on-site (AORCD4•machine•onsite•vs.offsite = 0.83, 95%CI [0.74-0.94]) and presence of PMTCT services onsite (AOR = 0.85, 95%CI [0.77-0.93]). Conclusion:: The risk of starting ART late remained persistently high. Efforts are needed to ensure identification and enrollment of patients at earlier stages of HIV disease. Individual and clinic level factors identified may provide clues for upstream structural interventions.
ACCESSION #
79460642

 

Related Articles

  • Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy with Concurrent Active TB or Other AIDS-Defining Disease. Périssé, André R. S.; Smeaton, Laura; Chen, Yun; La Rosa, Alberto; Walawander, Ann; Nair, Apsara; Grinsztejn, Beatriz; Santos, Breno; Kanyama, Cecilia; Hakim, James; Nyirenda, Mulinda; Kumarasamy, Nagalingeswaran; Lalloo, Umesh G.; Flanigan, Timothy; Campbell, Thomas B.; Hughes, Michael D. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background: Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy (ART) with concurrent active TB or other...

  • No Association of Cryptococcal Antigenemia with Poor Outcomes among Antiretroviral Therapy-Experienced HIV-Infected Patients in Addis Ababa, Ethiopia. Smitson, Christopher C.; Tenna, Admasu; Tsegaye, Mulugeta; Alemu, Abere S.; Fekade, Daniel; Aseffa, Abraham; Blumberg, Henry M.; Kempker, Russell R. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Introduction: There are limited data on clinical outcomes of ART-experienced patients with cryptococcal antigenemia. We assessed clinical outcomes of a predominantly asymptomatic, ART-experienced cohort of HIV+ patients previously found to have a high (8.4%) prevalence of cryptococcal...

  • Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. Giuliano, Marina; Andreotti, Mauro; Liotta, Giuseppe; Jere, Haswell; Sagno, Jean-Baptiste; Maulidi, Martin; Mancinelli, Sandro; Buonomo, Ersilia; Scarcella, Paola; Pirillo, Maria F.; Amici, Roberta; Ceffa, Susanna; Vella, Stefano; Palombi, Leonardo; Marazzi, Maria Cristina // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background:Optimized preventive strategies are needed to reach the objective of eliminating pediatric AIDS. This study aimed to define the determinants of residual HIV transmission in the context of maternal antiretroviral therapy (ART) administration to pregnant women, to assess infant safety...

  • Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy. Winston, Alan; Arenas-Pinto, Alejandro; Stöhr, Wolfgang; Fisher, Martin; Orkin, Chloe M.; Aderogba, Kazeem; De Burgh-Thomas, Andrew; O'Farrell, Nigel; Lacey, Charles JN.; Leen, Clifford; Dunn, David; Paton, Nicholas I. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Objective: To describe factors associated with neurocognitive (NC) function in HIV-positive patients on stable combination antiretroviral therapy. Design: We undertook a cross-sectional analysis assessing NC data obtained at baseline in patients entering the...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study. Panos, George; Samonis, George; Alexiou, Vangelis G.; Kavarnou, Garyfallia A.; Charatsis, Gerasimos; Falagas, Matthew E. // Current HIV Research;May2008, Vol. 6 Issue 3, p257 

    HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987-2006). The study was divided in pre-HAART and HAART period for...

  • HIV-Induced T-Cell Activation/Exhaustion in Rectal Mucosa Is Controlled Only Partially by Antiretroviral Treatment. Rueda, Cesar Mauricio; Velilla, Paula Andrea; Chougnet, Claire A.; Montoya, Carlos Julio; Rugeles, Maria Teresa // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Peripheral blood T-cells from untreated HIV-1-infected patients exhibit reduced immune responses, usually associated with a hyperactivated/exhausted phenotype compared to HAART treated patients. However, it is not clear whether HAART ameliorates this altered phenotype of T-cells in the...

  • Antiretroviral prescribing delayed among certain patients.  // PharmacoEconomics & Outcomes News;4/24/2004, Issue 451, p7 

    Discusses a study conducted by researchers in the U.S. in April 2004, which revealed the delay of antiretroviral therapy for nonadherent HIV-infected patients caused by physicians who follow guidelines on antiretroviral treatment. Number of patients with HIV infections that were evaluated;...

  • Partner protection. Coghlan, Andy // New Scientist;4/28/2012, Vol. 214 Issue 2862, p4 

    The article discusses a recommendation from the World Health Organization (WHO) to immediately give any person with HIV, whose partner is not infected, antiretroviral drugs to prevent HIV transmission.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics